Synthetic Phenolic Glycolipids for Application in Diagnostic Tests for Leprosy.
carbohydrates
diagnosis
glycoconjugates
lateral flow assay
leprosy
Journal
Chembiochem : a European journal of chemical biology
ISSN: 1439-7633
Titre abrégé: Chembiochem
Pays: Germany
ID NLM: 100937360
Informations de publication
Date de publication:
16 04 2021
16 04 2021
Historique:
revised:
16
12
2020
received:
06
12
2020
pubmed:
18
12
2020
medline:
15
12
2021
entrez:
17
12
2020
Statut:
ppublish
Résumé
Point-of-care (POC) diagnostic tests for the rapid detection of individuals infected with Mycobacterium leprae, the causative pathogen of leprosy, represent efficient tools to guide therapeutic and prophylactic treatment strategies in leprosy control programs, thus positively contributing to clinical outcome and reducing transmission of this infectious disease. Levels of antibodies directed against the M. leprae-specific phenolic glycolipid I (PGL-I) closely correlate with an individual's bacterial load and a higher risk of developing leprosy. We describe herein the assembly of a set of PGL glycans carrying the characteristic phenol aglycon and featuring different methylation patterns. The PGL trisaccharides were applied to construct neoglycoproteins that were used to detect anti-PGL IgM antibodies in leprosy patients. ELISAs and quantitative lateral-flow assays based on up-converting nanoparticles (UCP-LFAs) showed that the generated PGL-I and PGL-II trisaccharide neoglycoconjugates can be applied for the detection of anti M. leprae IgM antibodies in POC tests.
Identifiants
pubmed: 33332701
doi: 10.1002/cbic.202000810
pmc: PMC8248333
doi:
Substances chimiques
Antigens, Bacterial
0
Glycolipids
0
phenolic glycolipid I, Mycobacterium leprae
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1487-1493Subventions
Organisme : Netherlands Organisation for Scientific Research (NWO)
Informations de copyright
© 2020 The Authors. ChemBioChem published by Wiley-VCH GmbH.
Références
Clin Microbiol Rev. 2006 Apr;19(2):338-81
pubmed: 16614253
Infect Immun. 1984 Jan;43(1):245-52
pubmed: 6360898
Chembiochem. 2021 Apr 16;22(8):1487-1493
pubmed: 33332701
Clin Biochem. 2019 Apr;66:76-82
pubmed: 30695682
Carbohydr Res. 1987 Jun 1;163(1):41-52
pubmed: 3300972
Angew Chem Int Ed Engl. 2012 Nov 19;51(47):11774-7
pubmed: 23086739
PLoS One. 2013;8(1):e54874
pubmed: 23365681
Immunity. 2017 Sep 19;47(3):552-565.e4
pubmed: 28844797
Front Immunol. 2018 Jan 19;9:2
pubmed: 29403489
J Infect Dis. 1988 Apr;157(4):770-6
pubmed: 3346568
Clin Vaccine Immunol. 2016 Jun 06;23(6):515-519
pubmed: 27030588
Front Cell Infect Microbiol. 2014 Dec 09;4:173
pubmed: 25538905
Chembiochem. 2014 May 26;15(8):1176-82
pubmed: 24797221
J Clin Microbiol. 2003 May;41(5):1991-5
pubmed: 12734239
ACS Chem Biol. 2017 Dec 15;12(12):2990-3002
pubmed: 29048873
Front Immunol. 2019 Dec 17;10:2913
pubmed: 31921172
Am J Trop Med Hyg. 1998 Feb;58(2):133-6
pubmed: 9502593
J Dtsch Dermatol Ges. 2017 Aug;15(8):801-827
pubmed: 28763601
Bioorg Med Chem Lett. 2010 Jun 1;20(11):3250-3
pubmed: 20462755
Nihon Rai Gakkai Zasshi. 1991 Jul-Dec;60(3-4):132-8
pubmed: 1843226
Chembiochem. 2009 Jun 15;10(9):1486-9
pubmed: 19472251
Lepr Rev. 2011 Dec;82(4):344-57
pubmed: 22439275
Int J Lepr Other Mycobact Dis. 1999 Sep;67(3):243-9
pubmed: 10575403
Org Lett. 2003 May 1;5(9):1519-22
pubmed: 12713313
PLoS Negl Trop Dis. 2014 May 08;8(5):e2845
pubmed: 24810599
Sci Rep. 2017 Aug 21;7(1):8868
pubmed: 28827673
J Org Chem. 2015 Sep 4;80(17):8796-806
pubmed: 26230920
ACS Chem Biol. 2016 Oct 21;11(10):2865-2875
pubmed: 27548027
Chem Sci. 2015 May 1;6(5):3161-3172
pubmed: 28706688
Clin Vaccine Immunol. 2011 Feb;18(2):260-7
pubmed: 21177913
J Proteome Res. 2009 Jul;8(7):3529-38
pubmed: 19366269
Carbohydr Res. 1988 Dec 1;183(2):241-60
pubmed: 3063383
Carbohydr Res. 1986 Nov 15;156:39-56
pubmed: 3815408
Cell. 2017 Aug 24;170(5):973-985.e10
pubmed: 28841420
Chembiochem. 2013 Nov 4;14(16):2153-9
pubmed: 24115598
Curr Infect Dis Rep. 2017 Jun;19(6):23
pubmed: 28444521